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Abstract
Chronic myeloid leukemia (CML) was once a life-threatening disease in which the clonal 
expansion of leukemic myeloid cells occurs as a result of reciprocal chromosomal 
translocation between long arm of chromosome 9 and 22 (Philadelphia chromosome). The 
resulting fusion protein BCR-ABL shows constantly activated ABL tyrosine kinase activity 
which is essential for growth of leukemic cells. Specific inhibition of this activated tyrosine 
kinase by imatinib (Gleevec, Novartis) has completely changed the curability of the disease 
(Druker et al., 2001). Imatinib is designed to inhibit the binding of ATP to the ABL tyrosine 
kinase so as to abolish the phosphorylation of the downstream signal proteins. 
Chronic myeloid leukemia is one of the diseases of which the molecular mechanism of 
development has been best dissected. And the discovery of imatinib is truly a milestone 
and the victory for modern molecular medicine. Its amazing efficacy has transformed a 
disease with a formidable prognosis, CML, into a chronic condition with safety well 
established. Imatinib now being a standard therapy for CML, the history of the study of 
the molecular mechanism of CML, the discovery of the drug, and the related questions are 
discussed.
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 Chronic myeloid leukemia (CML) is a myelopro-
liferative disorder characterized by excessive 
accumulation of apparently normal myeloid cells. 
Its annual incidence is 1.0-1.5 per 100,000 persons 
and the median age of onset is 50-60 years. 
Children are rarely affected. Symptoms at 
presentation may include lethargy, weight loss, 
unusual bleeding, sweats, anemia, and splenome-
galy, but 50% of patients are asymptomatic at the 
time of diagnosis by the blood test. CML is 
characterized by the presence of the Philadelphia 
(Ph) chromosome which results from a (9; 22) (q34; 
 q11) reciprocal translocation. It juxtaposesthe c-
abl oncogene (ABL1) gene on chromosome 9 with 
the breakpoint cluster region  (BCR) gene on 
chromosome 22, generating BCR-ABL oncogene. 
It represents the constitutively activated c-abl 
tyrosine kinase, which gives growth advantage to 
a clonal leukemogenic hematopoietic ell. Before 
the advent of new drugs (c-abl tyrosine kinase 
inhibitors), the main topic of this article, all 
patients with the chronic phase of CML (CML-
CP), which represents the initial condition of the
tyrosine kinase, imatinib
disease, the massive accumulation of apparently 
normal myeloid cells, progressed spontaneously to 
advanced phase CML after a median interval of 
approximately 5 years. The advanced phase is 
divided into an initial accelerated phase (AP), 
during which patients may still respond to 
treatment for some months or sometimes years, 
and a subsequent, more aggressive, blastic phase 
(BP). The blastic phase of CML (CML-BP) is 
characterized by the condition called the "blast 
 crisis", a proliferation of more than 20% of 
myeloblasts or lymphoblasts in the blood or bone 
marrow. And its symptoms are very similar to 
those of acute leukemia. Patients with CML-BP 
have a median survival of approximately 6 
months. Therefore, according to this natural 
course of the disease, CML was indeed once a life-
threatening disease. In the past, before c-abl 
tyrosine kinase inhibitors (TKIs) treatment was 
introduced, antimetabolites (e. g., cytarabine, hy-
droxyurea), alkylating agents, interferon alfa 2b, 
and steroids were used. But the effect of these 
drugs was limited and far from satisfactory.
Oncogenic
tein
potential
of  BCR-ABL
AINO JOURNAL,
fusion  pro-
 CML was the first malignancy to be linked to a 
clear genetic abnormality, the chromosomal 
translocation known as the Philadelphia chromo-
some. Using a probe specific for the Philadelphia 
translocation breakpoint domain of one CML 
patient, a 46 kb human DNA fragment was 
molecularly cloned in 1984. Further analysis 
showed that the breakpoints were clustered 
within the 5.8 kb region of the DNA, for which it 
was named the "breakpoint cluster region  (BCR)" 
on chromosome 22 (Groffen et al., 1984). Later, 
this region was revealed to be within the gene 
named BCR. The counterpart gene of this 
reciprocal translocation is a gene known as v-abl 
Abelsone murine leukemia viral oncogene homo-
log (ABL1) on chromosome 9. As a result of this 
translocation, a new BCR-ABL fusion protein, 
p210, is formed. This BCR-ABL fusion protein, 
p210, is an oncogenic protein, which encodes a 
constitutively activated tyrosine kinase (Lugo et 
al., 1990), the stimulant for proliferation of myeloid 
cells to produce CML. 
 Oncogenic potential to myeloproliferative dis-
ease of this abnormal BCR-ABL fusion protein 
was confirmed in several p210 expression meth-
ods in mice (Daley et al., 1990; Pear et al., 1998). 
Retroivirus induced p210 BCR-ABL fusion protein 
was introduced into the bone marrow cells. 
These cells were transplanted into mice to 
efficiently reproduce CML-like myeloproliferative 
disease. These results showed the oncogenicity 
of BCR-ABL fusion protein and revealed the 
essential role of this fusion protein in the course of 
CML development. The fused BCR-ABL protein 
interacts with the interleukin 3 beta (c) receptor 
subunit. The BCR-ABL transcript is continuously 
active and does not require activation by other 
cellular messaging proteins. In turn, BCR-ABL 
activates a cascade of proteins that control cell 
cycle, speeding up cell division. Moreover, the 
BCR-ABL protein inhibits DNA repair, causing 
genomic instability and making the cell more 
susceptible to developing further genetic abnor-
malities.
BCR-ABL
target
tyrosine  kinase as a therapeutic
 Since BCR-ABL tyrosine kinase was identified 
as a key element of CML development, extensive 
search for specific BCR-ABL tyrosine kinase 
inhibitors (TKIs) was done in the late 1990s. The
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first of these to be developed was imatinib 
(marketed as Gleevec or Glivec; previously known 
as STI-571 or CGP57148B). The efficacy of 
imatinib was really excellent for newly diagnosed 
patients with CML in the chronic phase. Adverse 
effects of imatinib were minimal; the most 
common were nausea, myalgias, edema, and 
diarrhea (Druker et al., 2001). Thus, imatinib has 
been proven to inhibit the progression of CML, 
allowing the majority of patients (65-75%) to have 
a regrowth of their normal bone marrow. Several 
years ago, 5-year follow-up data on patients 
receiving imatinib for CML was published 
(Druker et al., 2006). According to this, the overall 
survival rate is 89% after five years. This rate is 
much better than that of the former standard 
treatment with interferon alfa plus cytarabine (a 
5-year overall survival of 68 to 70%) and imatinib 
treatment has made CML is the first cancer in 
which a medical treatment can give the treated 
patients a normal life expectancy. But an 
estimated 7-20% of patients progressed to the 
accelerated phase or blastic phase of CML. To 
overcome imatinib resistance and to increase the 
responsiveness of TKIs, two novel agents, dasati-
nib and nilotinible, were later developed. So there 
are now three drugs available for first-line 
treatment of CML.
 Human chronic myeloid leukemia stem cells
are  insensitiv to
 Imatinib therapy, which targets the oncogene 
product BCR-ABL, has transformed chronic 
myeloid leukemia (CML) from a life-threatening 
disease into a chronic condition. CML originates 
in a clonal hematopoietic stem cell (HSC) with the 
specific reciprocal translocation t(9; 22). Imatinib 
induces complete cytogenetic response (CCRs) in 
more than 80% of newly diagnosed patients in the 
chronic phase CML. But most patients have 
BCR-ABL transcripts. Even in patients with 
BCR-ABL transcripts undetectable by RT-PCR, 
active leukemia recurs when imatinib therapy is 
discontinued. This indicates that some leukemia 
cells persist in most patients even when they are 
free of overt CML. Therefore, the current 
recommendation is lifelong continuance of ther-
apy, at considerable cost and sometimes despite 
significant side effects. It is concluded that most 
patients harbor residual leukemia cells, and 
disease recurrence usually occurs when imatinib 
is discontinued. Although imatinib inhibits BCR-
ABL in CML stem and progenitor cells, human 
CML stem cells do not depend on BCR-ABL
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activity for survival and are thus not
by imatinib therapy (Corbin et al.,
CML treatment with imatinib
eliminated
2011).
treat CML-AP or CML-BP. And finally, to over-
come imatinib resistance during the ordinary 
course of treatment of CML-CP.
 Resistance to imatinib
Elimination of  leukemic stem cells
 Although a revolution in medical science was 
marked with the advent of imatinib, the emer-
gence of resistance to imatinib has dampened the 
enthusiasm for this drug to some extent. The 
rate of relapse and resistance appear to correlate 
with disease stage, and the incidence increases as 
CML progresses. According to the five-year 
follow-up data on receiving imatinib for the initial 
stage of CML, the rate of complete cytogenetic 
response might reach 87% after 60 months 
according to Kaplan-Meier estimates. And only 
7 % of patients showed imatinib resistance and 
progressed to the accelerated phase CML or blast 
crisis (Druker et al., 2006). Resistance to imatinib 
can be divided into primary resistance, in which 
patients show lack of efficacy to this tyrosine 
kinase inhibitor (TKI) from the start of the 
therapy, and secondary resistance, also known as 
acquired resistance, which is defined as a loss of 
hematologic (normalization of peripheral blood 
counts), cytogenetic (disappearance of Philadel-
phia chromosome), or molecular (undetectable 
BCR-ABL transcripts by RT-PCR) response. The 
mechanism of imatinib resistance is primarily 
associated with mutations within the tyrosine 
kinase domain of BCR-ABL fusion protein. The 
first mutation discovered with respect to imatinib 
resistance in American population was  T315I. To 
date, 17 distinct point mutations in the ABL 
kinase domain conferring resistance to imatinib 
have been identified. In summary, as long as the 
treatment with imatinib begins in the chronic 
phase of CML, the prognosis of patients is very 
good, and most patients do not show resistance to 
imatinib. But for patients in the accelerated or 
blastic phase of CML, imatinib therapy is not 
completely effective. Strategies to overcome 
imatinib resistance should be considered in those 
cases.
 How to overcome imatinib  resistance
 Now that imatinib therapy has been established 
as a standard treatment of CML, remaining 
endeavors are addressed to overcome imatinib 
resistance in its broad meaning. The main goals 
of present approaches can be classified into three 
categories. Firstly, to eradicate leukemia stem 
cells of CML, which remain potential sources of 
relapse. Secondly, to find a more effective way to
 Although imatinib successfully converts the 
life-threatening disease CML into a chronic 
condition, it is not a permanent cure of the disease 
because relapse is a common scenario with 
discontinuation of imatinib. The reason why it is 
so is the survival of quiescent leukemic stem cells, 
which are insensitive to imatinib. The bone 
marrow microenvironment supports survival of 
CML stem cells that are not oncogene addicted. 
Treatment with histone deacetylase inhibitor 
(HDA-Cis) combined with imatinib effectively 
induced apoptosis in quiescent CML progenitors 
resistant to elimination by imatinib alone (Zhang 
et al., 2010). Thus, combination therapy could be 
clinically more effective in the near future and 
might open the way to a complete cure.
Treatment of CML-AP or CML-BP
 The molecular mechanism of the CML emer-
gency is now fully dissected at the molecular level 
and is relatively simple. That is the main reason 
imatinib therapy is so successful. However, the 
molecular mechanism of progression of CML-CP 
to blast crisis is complicated and much more 
difficult to analyze. At present, its mechanisms 
underlying disease progression are still uncertain, 
but they most likely involve activation of oncogen-
ic factors and/or inactivation of tumor suppres-
sors. A plausible assumption is that BP is a 
multistep, time-dependent process initiated by 
both BCR-ABL-dependent and -independent DNA 
damage associated with inefficient and unfaithful 
DNA repair in CML-CP that leads to selection of 
one or more CML-BP clones. Indeed an increased 
level of BCR-ABL activity is known to cause 
genomic instability, which facilitates blastic trans-
formation. In the past, CML-BP was often treated 
with drugs used for acute leukemias. But patients 
usually relapsed within a few months. The 
introduction of TKIs has improved the prognosis 
to some degree. The majority of CML-BP 
patients not previously treated with TKIs do 
initially respond to treatment with these agents. 
But, again, most still relapse within a few months 
of achieving seemingly complete hematologic or 
even cytogenetic response. With these rather 
dismal results of CML-BP and the good clinical 
outcome of imatinib treatment of CML-CP, one 
might reasonably conclude that the best approach 
to CML-BP would be prevention. But, it should be
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noticed that there are still about 10% nonrespond-
ers to TKIs who inevitably progress to CML-
AP/CML-BP, and about  15% of CML patients are 
already in CML-AP/CML-BP at the time of 
diagnosis. Second generation TKIs (dasatinib and 
nilotinib) with more potent tyrosine kinase 
inhibitory potential show better initial hemato-
poietic response to CML-AP/CML-BP than imati-
nib, but relapse is a common following scenario, as 
mentioned before. Third generation TKIs (bosuti-
nib and ponatinib) are now in the pivotal phase 
 II/III clinical trial. Combination therapy with 
imatinib is also in progress. At present, any CML-
BP patient who does respond to modern therapy 
should proceed to allogeneic stem cell transplant, 
if possible, prior to relapse.
To overcome imatinib resistance in CML-CP
 Considering the poor prognosis of CML-BP, 
preventing CML-CP from progressing to a more 
advanced stage is very important. Therefore, 
how to overcome imatinib resistance in CML-CP 
is one of the key questions in modern CML 
treatment. The main cause of imatinib resistance 
comes from mutations within BCR-ABL. The 
second generation TKI, dasatinib, holds great 
promise for the management of practically all 
imatinib-resistant mutation in BCR-ABL except 
for  T315I mutation. Another second generation 
TKI, nilotinib, also failed to solve this problem. 
For the most troublesome mutant,  T315I, third 
generation TKI, ponatinib, has promising pre-
clinical research results and can inhibit the 
entire spectrum of mutations within BCR-ABL. 
Another, third generation TKI, bosutinib, is a dual 
Src-Abl inhibitor. Bosutinib is now in phase III 
clinical trials and has shown good activity in 
patients resistant to imatinib or other TKIs.
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inhibitor 2A/2B (CDKN2A/B) (50% of cases) and 
the Ikaros transcription factor  (IKZF1) (55% of 
cases) in lymphoid BP. At present, any one 
secondary genetic aberration is unlikely to be 
identified as a cause of blastic transformation. In 
addition to genetic aberration seen in blastic 
transformation of CML, epigenetic changes are 
also seen, which are mostly dependent on the 
pleiotropic effect of constitutive BCR-ABL activ-
ity. The level of BCR-ABL activity starts to 
increase in CML-AP and greatly perturbs the 
CML transcriptome and changes the gene ex-
pression profile. Among the activated are  MAPK
EPK1/2, MYC
, JAK2,  YES-1, LYN, hnRNP-
E2, MDM2, STAT5,  BMI-1, and BCL-2. On the 
other hand, P53, C/EBP , and PP2A are inhibited. 
The relatively high BCR-ABL expression level in 
CML stem cells is likely to trigger combined 
genetic and epigenetic abnormalities and leads to 
enhanced proliferation/self renewal, increased 
genomic instability, inhibition of tumor suppres-
sors, and blocked myeloid differentiation. With 
these complex mechanisms, blastic clones are 
finally selected to progress the disease.
Future perspective
 Considering the complex mechanism of blast 
crisis, I believe the easiest way to our goal, the 
complete cure of CML, is definitely the develop-
ment of more effective, and specific TKIs and 
administration of newly developed drugs before 
the progression of CML-CP. Indeed, second 
generation TKIs (nilotinib and dasatinib) showed 
impressive results not only in the treatment of 
patents resistant to imatinib but also in the 
treatment of newly diagnosed CML-CP patients 
(Table 1). The effective treatment of advanced 
stages of CML, CML-AP/CML-BP, will only be
 Mechanisms  of  blastic transformation of CML
  The genetic lesions observed in CML-BP 
patients in the past, and now since the introduc-
tion of TKIs, mostly include the presence of 
additional chromosomes, gene deletions, gene 
insertions, and/or point mutations (including BCR-
ABL mutations). But patterns differ in myeloblas-
tic and lymphoblastic transformations. At the 
molecular level, the most common mutations 
detectable (other than those in the BCR-ABL 
kinase domain) occur at the loci of the tumor 
suppressor genes P53 (20%-30% of cases) and the 
runt-related transcription factor gene  (RUNX1 
also known as AML1) (38% of cases) in myeloid 
BP and at the loci of cyclin-dependent kinase
Table 1 Compared responses to imatinib, nilotinib, and 
  dasatinib in newly diagnosed CML-CP patients
Treatment
Complete cytogenetic 
  response* (%)
Major molecular 
response* (%)
 Imatinib 
400 mg/day
72 22
 Nilotinib 
300 mg/day
 80**  44**
Dasatinib 
100 mg/day
83**  46**
* Complete cytogenetic response is defined as the absence of Ph-
 positive metaphases on the basis of G-banding and major molecular 
 response is defined as a reduction in the BCR-ABL transcript level by 
 at least 3 log (less than 0.1%) from the standardized base line level 
 measured by quantitative RT-PCR assay. The rates of responses 
 were measured at 12 months after initiation of each treatment. 
**Statistically significant difference in nilotinib/dasatinib versus imatinib.
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achieved when the critical biological process of 
progression of CML is identified, and the thera-
peutic methods impeding the process are devel-
oped. For a feasible future approach, other 
promising methods to target BCR-ABL are listed.
Targeting pathways downstream of BCR-ABL
 The RAS/RAF pathway is intimately linked to 
BCR-ABL through the adapter molecules GRB2 
and CRKL. Inhibitors of these molecules, such as 
a farnesyl transferase inhibitor, theoretically 
block the pathway.  P13K pathway is also in the 
BCR-ABL downstream. It causes increased 
production of reactive oxygen species and ge-
nomic instability. It can be blocked by inhibitors 
such as LY294002 or wortmannin.
Targeting  mRNA of BCR-ABL
 RNAi technology is a powerful tool in silencing 
gene function. The use of RNAi with breakpoint-
specific short-interfering RNA has been shown to 
selectively inhibit BCR-ABL dependent prolifera-
tion and enhance imatinib effect (Wohlbold et al., 
2003).
Conclusion
 As a student, in 1988, I attended the last lecture 
of the former head and professor of the division of 
hematology, department of internal medicine. I 
still cannot forget the concluding remarks in that 
lecture. He said  "Although great progress has 
been made in the treatment of acute leukemia, 
there has been no progress at all in the treatment 
of CML during these 50 years of my career in this 
 university." After the discovery of the Phila-
delphia chromosome by Nowell and Hungerford in 
1960, CML may be the most extensively studied 
human cancer. But, at that time, surely few might 
have expected that a breakthrough would be 
achieved within 20 years. A remarkable break-
through in cancer therapy came with the 
introduction of imatinib to the treatment for CML. 
Because CML is a hematopoietic stem cell
disorder, newly
the imatinib
developed methods to
resistance at the
level are most eagerly awaited.
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